Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Switzerland's Novocure Q3 revenue rises 16%, beats estimates

By Reuters News


Overview

  • Global oncology company's Q3 revenue rose 16% yr/yr, beating analyst expectations

  • Company raised full-year 2026 revenue and adjusted EBITDA guidance

  • Optune Pax approved in Japan for locally advanced pancreatic cancer


Outlook

  • Novocure raises 2026 net revenue guidance to $736 mln-$743 mln from $710 mln-$725 mln

  • Company lifts 2026 adjusted EBITDA forecast to $24 mln-$34 mln from $0 mln-$15 mln

  • Novocure expects quarterly gross margin in the mid-to-high 70s percent for 2026


Result Drivers

  • ACTIVE PATIENT GROWTH - Co said 19% global growth in active patients drove Q3 revenue increase

  • PRODUCT LAUNCHES IN NEW MARKETS - Co attributed record number of active patients to expanding portfolio and new market launches, per CEO Frank Leonard

  • ONE-TIME CLAIMS APPROVAL BENEFITS - Co recognized $4.4 mln in net revenue from one-time increases in claims approval rates in US and Germany


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$193.40 mln

$182.23 mln (7 Analysts)

Q3 Net Loss

$10.44 mln

Q3 Gross Profit

$148.87 mln

Q3 Operating Income

-$6.17 mln

Q3 Pretax Loss

$7.88 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for NovoCure Limited is $26.00, about 83.5% above its October 28 closing price of $14.17


Reuters Recommended Reads

  • Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

  • Oct 28 - Glaukos Q3 revenue jumps 58% on iDose TR, Epioxa launches, Corneal Health growth

  • Oct 28 - Straumann sees North America stabilising, China demand improving after Q3 beat


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.